Author,Reference,Extractor_1,duplicate,preDM_def,combined_def,n_def,subgroup,mort_report,cardiomort_report,CVD_report,CHD_report,stroke_report,HF_report,CKD_report,cohort_name,country,year_pub,years_study,mean_followup,multivar_adjust,var_adjust,n_participants,n_females,mean_age_1,mean_age_F,mean_age_M,FSG_unit,mean_FSG,mean_FSG_F,mean_FSG_M,percent_HBA1C,percent_HBA1C_F,percent_HBA1C_M,percent_CVD,percent_CVD_M,percent_CVD_F,mean_GFR,mean_GFR_F,mean_GFR_M,outcome_type,n_mort,n_mort_F,n_mort_M,HR_mort_F,LCI_mort_F,UCI_mort_F,HR_mort_M,LCI_mort_M,UCI_mort_M,n_cardiomort,n_cardiomort_F,HR_cardiomort_F,LCI_cardiomort_F,UCI_cardiomort_F,HR_cardiomort_M,LCI_cardiomort_M,UCI_cardiomort_M,n_stroke,n_stroke_F,HR_stroke_F,LCI_stroke_F,UCI_stroke_F,HR_stroke_M,LCI_stroke_M,UCI_stroke_M,n_iscstroke,n_iscstroke_F,HR_iscstroke_F,LCI_iscstroke_F,UCI_iscstroke_F,HR_iscstroke_M,LCI_iscstroke_M,UCI_iscstroke_M,n_hemstroke,n_hemstroke_F,HR_hemstroke_F,LCI_hemstroke_F,UCI_hemstroke_F,HR_hemstroke_M,LCI_hemstroke_M,UCI_hemstroke_M,CVD_def,n_CVD,n_CVD_F,HR_CVD_F,LCI_CVD_F,UCI_CVD_F,HR_CVD_M,LCI_CVD_M,UCI_CVD_M,CHD_def,n_CHD,n_CHD_F,HR_CHD_F,LCI_CHD_F,UCI_CHD_F,HR_CHD_M,LCI_CHD_M,UCI_CHD_M,CKD_def,n_CKD,n_CKD_F,HR_CKD_F,LCI_CKD_F,UCI_CKD_F,HR_CKD_M,LCI_CKD_M,UCI_CKD_M,n_HF,n_HF_F,HR_HF_F,LCI_HF_F,UCI_HF_F,HR_HF_M,LCI_HF_M,UCI_HF_M
"European Diabetes Epidemiology Group, 2001",3. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161(3):397-405.,Tyler,1,1,NA,1,6.1-6.9 mmol/L,1,1,0,0,0,0,0,DECODE,Europe (various),2001,NA,NA,1,"age, center, BMI, systolic blood pressure, serum cholesterol level, smoking status",21062,6686,53,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,485.58,27.9,,1.2,0.81,1.79,1.1,0.99,1.22,138.929,11.16,1.53,0.81,2.9,1.03,0.85,1.25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"European Diabetes Epidemiology Group, 2001",3. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161(3):397-405.,Tyler,1,2,NA,1,7.8 - 11 mmol/L,1,1,0,0,0,0,0,DECODE,Europe (various),2001,NA,NA,1,"age, center, BMI, systolic blood pressure, serum cholesterol level, smoking status",21062,6623,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,558.944,95.172,,1.25,0.98,1.58,1.42,1.28,1.57,192.31,38.808,1.28,0.88,1.86,1.34,1.12,1.6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Hu et al., 2003",10. Hu G. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia 2003;46(5):608-17.,Modupe,2,5,WHO FPG + OGTT 2hPG ,1,PreDM,1,1,0,0,0,0,0,DECODE,Europe (various),2003,NA,8.3,1,"adjusted for age, centre, BMI, systolic blood pressure, total cholesterol and smoking.",16482,8867,55.30532702,55.39290628,55.20334865,0,5.344509162,5.27322657,5.43,,NA,NA,NA,NA,NA,NA,NA,NA,0,1606,584,,1.31,NA,NA,1.19,NA,NA,613,186,1.25,NA ,NA,1.25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"McNeill et al., 2005","18. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005;28(2):385-90.",Tyler,3,0,NA,0,100-125 mg/dL,0,0,0,1,0,0,0,ARIC,USA,2005,1987-1999,11,1,"age, race/ARIC center, LDL cholesterol, and smoking.",12089,6881,54,54,54,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.9,1.25,2.89,1.52,1.05,2.18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Incident CHD included fatal or nonfatal hospitalized myocardial infarction, fatal CHD, silent myocardial infarction identified by electrocardiography, or coronary revascularization.",NA,NA,2.11,1.64,2.72,1.39,1.18,1.63,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"McNeill et al., 2006","24. McNeill AM, Katz R, Girman CJ, Rosamond WD, Wagenknecht LE, Barzilay JI, et al. Metabolic syndrome and cardiovascular disease in older people: The cardiovascular health study. J Am Geriatr Soc 2006;54(9):1317-24.",Modupe,4,1,NA,1,6.1-6.9 mmol/L,0,0,0,1,0,0,0,CHS (cardiovascular health study),USA,2006,1989-2001,11,1,adjusted for age and race.,3585,2229,72,72.06078959,73.01017699,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"first occurrence of angina pectoris, MI, CABG, or angioplasty or CHD death.",116,60,1.31,1.02,1.68,1.45,1.15,1.83,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"McNeill et al., 2006","24. McNeill AM, Katz R, Girman CJ, Rosamond WD, Wagenknecht LE, Barzilay JI, et al. Metabolic syndrome and cardiovascular disease in older people: The cardiovascular health study. J Am Geriatr Soc 2006;54(9):1317-24.",,4,0,NA,1,5.6-6.9 mmol/L,0,0,0,1,0,0,0,CHS (cardiovascular health study),USA,2006,1989-2001,11,1,adjusted for age and race.,3585,2229,72,72.06078959,73.01017699,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"first occurrence of angina pectoris, MI, CABG, or angioplasty or CHD death.",264,139,1.08,0.89,1.31,1.28,1.05,1.57,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Doi et al., 2010","47. Doi Y, Ninomiya T, Hata J, Fukuhara M, Yonemoto K, Iwase M, et al. Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 2010;41(2):203-9.",Modupe,5,2,NA,1,7.8-11.0 mmol/L,0,0,0,1,1,0,0,Hisayama study,Japan ,2009,1988-2002,14,1,"Multivariable adjustment was made for age, systolic blood pressure, electrocardiogram abnormalities, body mass index, total and high-density lipoprotein cholesterol, smoking habits, alcohol intake, and regular exercise.",2130.165,1249.752,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,13,0.88,0.46,1.7,0.91,0.44,1.89,NA,NA,NA,NA,NA,NA,NA,NA,"Combination of CHD and Ischemic stroke: CHD included acute myocardial infarction, silent myocardial infarction, sudden cardiac death within 1 hour after the onset of acute illness, and coronary artery disease treated by coronary artery bypass surgery or angioplasty.In principle, stroke was defined as a sudden onset of nonconvulsive and focal neurological deficit persisting for  24 hours. The diagnosis and classification of stroke were determined on the basis of clinical information, including brain CT and MRI, cerebral angiography, echocardiography, carotid duplex imaging, or autopsy findings.",48,19,NA,NA,NA,NA,NA,NA,"CHD included acute myocardial infarction, silent myocardial infarction, sudden cardiac death within 1 hour after the onset of acute illness, and coronary artery disease treated by coronary artery bypass surgery or angioplasty.",24,6,0.82,0.31,2.15,1.11,0.62,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Doi et al., 2010","47. Doi Y, Ninomiya T, Hata J, Fukuhara M, Yonemoto K, Iwase M, et al. Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 2010;41(2):203-9.",,5,1,NA,1,6.1-6.9 mmol/L,0,0,0,1,1,0,0,Hisayama study,Japan ,2009,1988-2002,14,1,"Multivariable adjustment was made for age, systolic blood pressure, electrocardiogram abnormalities, body mass index, total and high-density lipoprotein cholesterol, smoking habits, alcohol intake, and regular exercise.",2130.165,1249.752,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,7,1.89,0.82,4.34,0.41,0.1,1.74,NA,NA,NA,NA,NA,NA,NA,NA,"Combination of CHD and Ischemic stroke: CHD included acute myocardial infarction, silent myocardial infarction, sudden cardiac death within 1 hour after the onset of acute illness, and coronary artery disease treated by coronary artery bypass surgery or angioplasty.In principle, stroke was defined as a sudden onset of nonconvulsive and focal neurological deficit persisting for  24 hours. The diagnosis and classification of stroke were determined on the basis of clinical information, including brain CT and MRI, cerebral angiography, echocardiography, carotid duplex imaging, or autopsy findings.",15,8,NA,NA,NA,NA,NA,NA,"CHD included acute myocardial infarction, silent myocardial infarction, sudden cardiac death within 1 hour after the onset of acute illness, and coronary artery disease treated by coronary artery bypass surgery or angioplasty.",6,1,0.48,0.06,3.76,0.8,0.31,2.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Khang et al., 2010","48. Khang YH, Cho SI, Kim HR. Risks for cardiovascular disease, stroke, ischaemic heart disease, and diabetes mellitus associated with the metabolic syndrome using the new harmonised definition: findings from nationally representative longitudinal data from an Asian population. Atherosclerosis 2010;213(2):579-85.",Tyler,6,0,NA,0,100-125 mg/dl,0,0,1,1,1,0,0,K-NHANES,South Korea,2010,1998-2005,5.8,1,"model I adjusted for survey year (1998 and 2001) and age (age and age squared); model II adjusted for cigarette smoking, LDL cholesterol, alcohol consumption, and physical exercise as well as the covariates in model I; model III adjusted for socioeconomic status (education and household income), marital status, family history, and resting heart rate as well as the covariates in model II.",9791,5400,43.21030538,43.3,43.1,1,93.86908385,93.6,94.20,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,184,96,0.83,0.55,1.27,0.83,0.54,1.29,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,stroke and ischaemic heart disease constituted cardiovascular disease,288,142,0.93,0.66,1.3,0.92,0.66,1.29,"ICD codes for ischaemic heart disease (I20–I25),",122,59,1.34,0.8,2.25,1.04,0.63,1.73,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Kokubo et al., 2010","49. Kokubo Y, Okamura T, Watanabe M, Higashiyama A, Ono Y, Miyamoto Y, et al. The combined impact of blood pressure category and glucose abnormality on the incidence of cardiovascular diseases in a Japanese urban cohort: the Suita Study. Hypertens Res 2010;33(12):1238-43.",Tomiwa,7,0,NA,0,5.6-6.9 mmol/L,0,0,1,1,1,0,0,Suita study,Japan ,2010,1989-1994,11.7,1,"Age, BMI, hypertension, hyperlipidemia, smoking and drinking status",5069,2737,54.28112054,53.56265985,55.12435678,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,28,1.36,0.84,2.19,0.97,0.64,1.46,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,CVD was defined as stroke or CHD,139,48,1.49,1.02,2.16,1.13,0.85,1.51,"The criteria for a diagnosis of CHD included first ever acute myocardial infarction, sudden cardiac death within 24 h after the onset of acute illness or coronary artery disease followed by coronary artery bypass surgery or angioplasty",70,20,1.83,1.01,3.32,1.31,0.87,1.96,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Magliano et al., 2010","50. Magliano DJ, Soderberg S, Zimmet PZ, Cartensen B, Balkau B, Pauvaday V, et al. Mortality, all-cause and cardiovascular disease, over 15 years in multiethnic mauritius: impact of diabetes and intermediate forms of glucose tolerance. Diabetes Care 2010;33(9):1983-9.",Tyler,8,1,NA,1,6.1-6.9 mmol/L,1,1,0,0,0,0,0,NA,Mauritius,2010,1987-2007,15.1,1,"Waist/hip circumference, smoking, hypertension, ethnicity, prior CVD, education, HDL cholesterol, triglycerides, total cholesterol",8793,4623,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,0.9,0.56,1.45,1.13,0.82,1.56,NA,NA,0.66,0.32,1.38,1.24,0.82,1.87,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"We defined CVD mortality to include deaths categorized as cardiac, cerebrovascular, hypertension, and renal failure as the primary cuase of death. ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Magliano et al., 2010","50. Magliano DJ, Soderberg S, Zimmet PZ, Cartensen B, Balkau B, Pauvaday V, et al. Mortality, all-cause and cardiovascular disease, over 15 years in multiethnic mauritius: impact of diabetes and intermediate forms of glucose tolerance. Diabetes Care 2010;33(9):1983-9.",Tyler,8,2,NA,1,7.8 - 11.1 mmol/L,1,1,0,0,0,0,0,NA,Mauritius,2010,1987-2007,15.1,1,"Waist/hip circumference, smoking, hypertension, ethnicity, prior CVD, education, HDL cholesterol, triglycerides, total cholesterol",8793,4623,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,1.21,0.96,1.53,1.39,1.12,1.71,NA,NA,1.16,0.84,1.59,1.37,1.02,1.83,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"We defined CVD mortality to include deaths categorized as cardiac, cerebrovascular, hypertension, and renal failure as the primary cuase of death. ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Madssen et al., 2012","58. Madssen E, Vatten L, Nilsen TI, Midthjell K, Wiseth R, Dale AC. Abnormal glucose regulation and gender-specific risk of fatal coronary artery disease in the HUNT 1 study. Scand Cardiovasc J 2012;46(4):219-25.",Kuralay,9,5,WHO FPG + OGTT 2hPG ,1,PreDM,1,1,0,0,0,0,0,HUNT 1,Norway,2012,1984-2003,18,1,"Age, BMI, hypertension, established cardiovascular disease, smoking habits, exercise sessions per week",45530,23381,59.49654733,59.87167358,59.10055533,0,NA,NA,NA,NA,NA,NA,9.66,11.87017924,7.568260553,NA,NA,NA,0,NA,NA,,1.3,NA,1.04,1.6,1.04,1.2,66,20,1.2,0.8,1.9,1.2,0.9,1.6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Gordon-Dseagu et al., 2015","68. Gordon-Dseagu VL, Mindell JS, Steptoe A, Moody A, Wardle J, Demakakos P, et al. Impaired glucose metabolism among those with and without diagnosed diabetes and mortality: a cohort study using Health Survey for England data. PLoS One 2015;10(3):e0119882.",Modupe,10,3,NA,0,5.7-<6.5% (39-<48 mmol/mol),1,1,0,0,0,0,0,HSE,UK,2015,2003-2008,7,1,"Age, sex, smoking status, SES, BMI",20674,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,0.99,0.83,1.18,0.92,0.77,1.09,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,NA,NA,1.06,0.76,1.46,1.08,0.81,1.45,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Hadaegh et al., 2015","69. Hadaegh F, Ehteshami-Afshar S, Hajebrahimi MA, Hajsheikholeslami F, Azizi F. Silent coronary artery disease and incidence of cardiovascular and mortality events at different levels of glucose regulation; results of greater than a decade follow-up. Int J Cardiol 2015;182:334-9.",Fatima,11,5,ADA FPG + OGTT 2hPG ,1,PreDM,1,0,1,1,0,0,0,TLGS,Iran,2015,1999-2012,12.1,1,"Age, hypertension, hypercholesterolemia, BMI, smoking",1538,815,59.51252276,58.55920245,60.58715076,0,5.15130039,5.158834356,5.16,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,58,25,,1.35,0.78,2.3,0.99,0.64,1.55,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"composite measure of any CHD events, stroke, or cerebrovascular events",120,60,1.67,1.16,2.41,0.863,0.63,1.29,"Cases of definite MI diagnosed by ECG and biomarkers, probable MI, unstable angina pectoris, and angiographic proven CHD.",102,54,1.8,1.21,2.68,0.83,0.58,1.18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Warren et al., 2017","82. Warren B, Pankow JS, Matsushita K, Punjabi NM, Daya NR, Grams M, et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol 2017;5(1):34-42.",Tomiwa,12,2,NA,1,7.8 - 11.0 mmol/L,1,0,1,0,0,0,0,ARIC,USA,2017,1987-2013,NA,1,"Adjusted for age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, Forsyth County, NC; white, Forsyth County, NC), education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-lowering medication use (yes, no), family history of diabetes (yes, no)school, high school or equivalent, college or above), BMI, waist-to-hip ratio, total cholesterol, HDL, triglycerides, hypertension , eGFR, smoking status (current, former, never), drinking status (current, former,
never), lipid-lowering medication use  family history of diabetes ",6451,3718,62.56713688,NA,NA,0,5.347198884,NA,NA,NA,NA,NA,NA,NA,NA,88.22456983,NA,NA,0,491,NA,,1.08,0.91,1.28,1.27,1.09,1.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Incident atherosclerotic cardiovascular disease events were adjudicated and included any coronary heart disease hospital admission or death, or ischaemic stroke hospital admission or death, and were obtained by continuous active surveillance",217,NA,0.91,0.71,1.18,1.03,0.81,1.29,NA,NA,NA,NA,NA,NA,NA,NA,NA,Glomerular filtration rate (eGFR) of <60ml/min per 1.73 m2 measured at a study visit and a reduction in eGFR of at least 25% from the baseline visit to the follow up visit ,429,NA,1.11,0.94,1.32,1.04,0.86,1.25,NA,NA,NA,NA,NA,NA,NA,NA
"Warren et al., 2017","82. Warren B, Pankow JS, Matsushita K, Punjabi NM, Daya NR, Grams M, et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol 2017;5(1):34-42.",Tomiwa,12,0,NA,1,5.6-6.9 mmol/L,1,0,1,0,0,0,0,ARIC,USA,2017,1987-2013,NA,1,"Adjusted for age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, Forsyth County, NC; white, Forsyth County, NC), education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-lowering medication use (yes, no), family history of diabetes (yes, no)school, high school or equivalent, college or above), BMI, waist-to-hip ratio, total cholesterol, HDL, triglycerides, hypertension , eGFR, smoking status (current, former, never), drinking status (current, former,
never), lipid-lowering medication use  family history of diabetes ",6862,4007,62.76243078,NA,NA,0,5.374060041,NA,NA,NA,NA,NA,NA,NA,NA,88.23121539,NA,NA,0,523,NA,,1.27,1.08,1.51,1.01,0.87,1.17,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Incident atherosclerotic cardiovascular disease events were adjudicated and included any coronary heart disease hospital admission or death, or ischaemic stroke hospital admission or death, and were obtained by continuous active surveillance",269,NA,1.17,0.91,1.5,1.06,0.86,1.31,NA,NA,NA,NA,NA,NA,NA,NA,NA,Glomerular filtration rate (eGFR) of <60ml/min per 1.73 m2 measured at a study visit and a reduction in eGFR of at least 25% from the baseline visit to the follow up visit ,453,NA,0.97,0.82,1.15,0.87,0.74,1.03,NA,NA,NA,NA,NA,NA,NA,NA
"Ahn et al., 2018","83. Ahn SV, Kim HC, Nam CM, Suh I. Sex difference in the effect of the fasting serum glucose level on the risk of coronary heart disease. J Cardiol 2018;71(2):149-154.",Kuralay,13,0,NA,0,100-109 mg/dL,0,0,0,1,0,0,0,KMIC,South Korea,2018,1990-2003,11,1,"Age, BMI, blood pressure, total cholesterol level, cigarette smoking status",155924,59077,43.84701136,42.35622831,44.75639411,1,88.15237167,85.43012509,89.81,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Defined by ICD-10 codes 120-125: angina, pectoris, acute myocardial infarction (MI), subsequent acute MI, other acute ischemic heart disease, and chronic ischemic heart disease",366,49,1.17,0.9,1.52,1,0.9,1.12,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Ahn et al., 2018","83. Ahn SV, Kim HC, Nam CM, Suh I. Sex difference in the effect of the fasting serum glucose level on the risk of coronary heart disease. J Cardiol 2018;71(2):149-154.",,13,0,NA,0,110-125 mg/dL,0,0,0,1,0,0,0,KMIC,South Korea,2018,1990-2003,11,1,"Age, BMI, blood pressure, total cholesterol level, cigarette smoking status",155924,59077,43.84701136,42.35622831,44.75639411,1,88.15237167,85.43012509,89.81,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Defined by ICD-10 codes 120-125: angina, pectoris, acute myocardial infarction (MI), subsequent acute MI, other acute ischemic heart disease, and chronic ischemic heart disease",180,19,1.62,1.11,2.36,1.07,0.92,1.25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Ares et al., 2019","86. Ares J, Valdes S, Botas P, Sanchez-Ragnarsson C, Rodriguez-Rodero S, Morales-Sanchez P, et al. Mortality risk in adults according to categories of impaired glucose metabolism after 18 years of follow-up in the North of Spain: The Asturias Study. PLoS One 2019;14(1):e0211070.",Kuralay,14,2,NA,1,7.8-11.0 mmol/L,1,1,0,0,0,0,,Asturias Study,Spain,2019,1998-1999,18,1,"Age, sex, BMI, history of high BP, smoking habits, LDL-C, glomerular filtration rate, and the prior presence of cardiovascular disease",903,505,51.72735327,NA,NA,1,94.51694352,NA,NA,5.09833887,NA,NA,3.433001107,NA,NA,79.98593577,NA,NA,0,62,NA,,0.96,0.56,1.62,0.89,0.55,1.41,74,39,1.04,0.44,2.5,1.35,0.58,3.15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Parizadeh et al., 2019","90. Parizadeh D, Rahimian N, Akbarpour S, Azizi F, Hadaegh F. Sex-specific clinical outcomes of impaired glucose status: A long follow-up from the Tehran Lipid and Glucose Study. Eur J Prev Cardiol 2019;26(10):1080-1091.",Ayo,15,0,NA,1,5.6-6.9 mmol/L,1,0,0,1,1,0,1,TLGS,Iran,2019,1999-2005,12,1,"age, body mass index, education level, waist/hip ratio, total cholesterol, high-density lipoprotein cholesterol, triglycerides, estimated glomerular filtration rate, smoking, lipid-lowering drug, prevalent cardiovascular disease; additional adjustments were ahypertension, family history of diabetes;",3198,NA,NA,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,,,,1.26,0.83,1.9,1.18,0.88,1.64,NA,NA,NA,NA,NA,NA,NA,NA,124,54,0.61,0.28,1.27,1.31,0.72,2.38,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,586,215,1.57,1.14,2.16,0.98,0.73,1.31,,1140,758,0.83,0.67,1.02,1.11,0.83,1.5,NA,NA,NA,NA,NA,NA,NA,NA
"Rhee et al., 2020","95. Rhee EJ, Jung I, Kwon H, et al. Increased Mortality Burden in Young Asian Subjects with Dysglycemia and Comorbidities. J Clin Med. 2020;9: pii: E1042.",Tyler,16,0,NA,0,100-125 mg/dL,1,0,0,0,0,0,0,NHIS (KNHS),South Korea,2020,2009-2016,7.3,1,"age, sex, current smoking, alcohol drinking, regular exercise, body mass index, hypertension, dyslipidemia and chronic kidney disease","5,617,468","2,473,828",47,NA,NA,1,NA,NA,NA,NA,NA,NA,2.80%,NA,NA,NA,NA,NA,0,52650,17024,,1.061,1.042,1.081,1.044,1.031,1.058,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Onat et al., 2013","62. Onat A, Can G, Cicek G, Ayhan E, Dogan Y, Kaya H. Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes, and coronary disease in non-diabetic adults. Acta Diabetol 2013;50(4):519-28.",James,17,1,NA,1,6.1-7.0 mmol/L,0,0,0,1,0,0,0,TARF,Turkey,2011,1997-2010,7.24,1,"sex, age and glucose categories for incident type-2 diabetes, in non-diabetic sample at baseline, in two models",2619,1343,47.84360443,47.6,48.1,mmol/L,5.310576556,5.5,5.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"based on the presence of angina pectoris, of a history of myocardial infarction with or without accompanying Minnesota codes of the ECG [24] or on a history of myocardial revascularization.",294,142,1.15,0.55,2.41,0.78,0.34,1.82,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Onat et al., 2013","62. Onat A, Can G, Cicek G, Ayhan E, Dogan Y, Kaya H. Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes, and coronary disease in non-diabetic adults. Acta Diabetol 2013;50(4):519-28.",James,17,2,NA,1,7.8-11.1 mmolL,0,0,0,1,0,0,0,TARF,Turkey,2011,1997-2010,7.24,1,"sex, age and glucose categories for incident type-2 diabetes, in non-diabetic sample at baseline, in two models",2619,1343,47.84360443,47.6,48.1,mmol/L,5.310576556,5.5,5.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"based on the presence of angina pectoris, of a history of myocardial infarction with or without accompanying Minnesota codes of the ECG [24] or on a history of myocardial revascularization.",294,142,3.74,1.16,12,1.86,0.69,5.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Kim et al., 2013","60. Kim HK, Kim CH, Kim EH, Bae SJ, Choe J, Park JY, et al. Impaired fasting glucose and risk of cardiovascular disease in Korean men and women: the Korean Heart Study. Diabetes Care 2013;36(2):328-35.",James,18,0,NA,0,100-109 mg/dL,0,0,1,1,1,0,0,Korean Heart Study,South Korea,2013,1996-2004,10,1,"age, systolic blood pressure, antihypertensive medication, LDL cholesterol, HDL cholesterol, current smoking, BMI, and family history of CVD.","357,407",140651.667,45.39060763,NA,NA,1,90.75195813,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,954,352,NA,NA,NA,NA,NA,NA,648,238,1,0.87,1.16,1.03,0.92,1.16,306,114,1.06,0.86,1.3,1.05,0.89,1.23,NA,5107,1898,0.96,0.89,1.04,1.1,1.05,1.17,NA,1712,526,1.09,0.99,1.2,1.06,0.99,1.13,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Kim et al., 2013","60. Kim HK, Kim CH, Kim EH, Bae SJ, Choe J, Park JY, et al. Impaired fasting glucose and risk of cardiovascular disease in Korean men and women: the Korean Heart Study. Diabetes Care 2013;36(2):328-35.",James,18,0,NA,0,110-125 mg/dL,0,0,1,1,1,0,0,Korean Heart Study,South Korea,2013,1996-2004,10,1,"age, systolic blood pressure, antihypertensive medication, LDL cholesterol, HDL cholesterol, current smoking, BMI, and family history of CVD.","357,407",140651.667,45.39060763,NA,NA,1,90.75195813,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,482,145,NA,NA,NA,NA,NA,NA,347,109,1.07,0.88,1.31,1.24,1.08,1.43,135,36,0.82,0.59,1.16,1.17,0.94,1.45,NA,2360,749,0.96,0.89,1.04,1.1,1.05,1.17,NA,801,197,0.97,0.84,1.13,1.18,1.08,1.29,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Donahue et al., 2011","10. Donahue RP, Dorn JM, Stranges S, Swanson M, Hovey K, Trevisan M. Impaired fasting glucose and recurrent cardiovascular disease among survivors of a first acute myocardial infarction: evidence of a sex difference? The Western New York experience. Nutr Metab Cardiovasc Dis 2011;21(7):504-11.",James,19,0,NA,0,100-125 mg/dL,0,0,0,1,1,0,0,Western New York Acute MI Study,USA,2011,1996-2004,4.5,1,"Adjusted for age, current smoker (yes vs. otherwise), Ever use alcohol (yes vs. otherwise), hypertension(yes vs. otherwise), hypercholesterolemia (yes vs. otherwise), aspirin use (yes vs. otherwise), BMI (continuous).",1226,348,55.08466558,56.44827586,54.54419134,1,110.3620718,116.1508621,108.07,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,264,91,2.24,1.2,4.18,0.83,0.57,1.21,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Kim et al., 2016","Association of prediabetes, defined by fasting glucose, HbA1c only, or combined criteria, with the risk of cardiovascular disease in Koreans Hong-Kyu KIM,1 Jung Bok LEE,2 Seon Ha KIM,3 Min-Woo JO,3 Eun Hee KIM,1 Jenie Yoonoo HWANG,1 Sung Jin BAE,1 Chang Hee JUNG,4 Woo Je LEE,4 Joong-Yeol PARK,4 Gyung-Min PARK,5 Young-Hak KIM5 and Jaewon CHOE1",James,20,0,NA,1,100-125 mg/dL,0,0,1,1,0,0,0,NA,South Korea,2015,2007-2011,3.1,1,"MV-adjusted HRs were adjusted for age, sex, hypertension, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, smoking, a family history of CVD, and body mass index.",76434,32685,47.5,NA,NA,0,5.48,NA,NA,5.5,NA,NA,NA,NA,NA,NA,NA,NA,0,88,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,105,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"were also defined as a composite of cardiovascular death, MI, stroke (hemorrhagic and ischemic), coronary revascularization, and hospitalization with IHD",222,NA,1.39,0.95,2.04,0.95,0.75,1.22,"Cardiovascular death, MI, revascularization, and hospitalization with IHD were classified as major IHD events",120,NA,1.97,0.97,3.99,0.92,0.71,1.21,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Kim et al., 2016","Association of prediabetes, defined by fasting glucose, HbA1c only, or combined criteria, with the risk of cardiovascular disease in Koreans Hong-Kyu KIM,1 Jung Bok LEE,2 Seon Ha KIM,3 Min-Woo JO,3 Eun Hee KIM,1 Jenie Yoonoo HWANG,1 Sung Jin BAE,1 Chang Hee JUNG,4 Woo Je LEE,4 Joong-Yeol PARK,4 Gyung-Min PARK,5 Young-Hak KIM5 and Jaewon CHOE1",James,20,3,NA,1,5.7%-6.4%,0,0,1,1,0,0,0,NA,South Korea,2015,2007-2011,3.1,1,"MV-adjusted HRs were adjusted for age, sex, hypertension, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, smoking, a family history of CVD, and body mass index.",76434,32685,47.5,NA,NA,0,5.48,NA,NA,5.5,NA,NA,NA,NA,NA,NA,NA,NA,0,65,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"were also defined as a composite of cardiovascular death, MI, stroke (hemorrhagic and ischemic), coronary revascularization, and hospitalization with IHD",191,NA,1.18,0.79,1.77,1.22,0.94,1.59,"Cardiovascular death, MI, revascularization, and hospitalization with IHD were classified as major IHD events",112,NA,2.27,1.1,4.7,1.54,1.17,2.03,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Kim et al., 2016","Association of prediabetes, defined by fasting glucose, HbA1c only, or combined criteria, with the risk of cardiovascular disease in Koreans Hong-Kyu KIM,1 Jung Bok LEE,2 Seon Ha KIM,3 Min-Woo JO,3 Eun Hee KIM,1 Jenie Yoonoo HWANG,1 Sung Jin BAE,1 Chang Hee JUNG,4 Woo Je LEE,4 Joong-Yeol PARK,4 Gyung-Min PARK,5 Young-Hak KIM5 and Jaewon CHOE1",James,20,5,ADA FPG + ADA HbA1c,1,100-125 mg/dL OR 5.7%-6.4%,0,0,1,1,0,0,0,NA,South Korea,2015,2007-2011,3.1,1,"MV-adjusted HRs were adjusted for age, sex, hypertension, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, smoking, a family history of CVD, and body mass index.",76434,32685,47.5,NA,NA,0,5.48,NA,NA,5.5,NA,NA,NA,NA,NA,NA,NA,NA,0,113,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,194,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"were also defined as a composite of cardiovascular death, MI, stroke (hemorrhagic and ischemic), coronary revascularization, and hospitalization with IHD",,NA,1.48,1.02,2.16,1.99,0.78,1.26,"Cardiovascular death, MI, revascularization, and hospitalization with IHD were classified as major IHD events",168,NA,3.01,1.36,6.68,1.17,0.89,1.52,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Huang et al., 2020","Huang YQ, Liu L, Huang JY, Chen CL, Yu YL, Lo K, Feng YQ. Prediabetes and risk for all-cause and cardiovascular mortality based on hypertension status. Ann Transl Med 2020;8(23):1580. doi: 10.21037/atm-20-1155",James,21,5,ADA FPG + ADA HbA1c,1,PreDM(+) & HTN(+),1,1,0,0,0,0,0,1999-2014 NHANES,China,2020,1994-2014,8.4,1,"Adjusted for age, gender, smoking, education, race, body mass index, cardiovascular disease at baseline, cancer at baseline, total cholesterol, high-density-lipoprotein cholesterol, energy intake, estimated glomerular filtration rate, the use of statin, antiplatelet drugs. CVD, cardiovascular disease; DM, diabetes mellitus; HTN, hypertension; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; CI, confidence interval.",34047,17613,44.6,NA,NA,1,NA,NA,NA,NA,NA,NA,7.4,NA,NA,92.1,NA,NA,0,1115,480,,1.29,1.07,1.56,1.41,1.21,1.63,227,89,2.28,1.24,4.2,1.96,1.32,2.9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Huang et al., 2020","Huang YQ, Liu L, Huang JY, Chen CL, Yu YL, Lo K, Feng YQ. Prediabetes and risk for all-cause and cardiovascular mortality based on hypertension status. Ann Transl Med 2020;8(23):1580. doi: 10.21037/atm-20-1155",James,21,5,ADA FPG + ADA HbA1c,1,PreDM(+) & HTN(-),1,1,0,0,0,0,0,1999-2014 NHANES,China,2020,1994-2014,8.4,1,"Adjusted for age, gender, smoking, education, race, body mass index, cardiovascular disease at baseline, cancer at baseline, total cholesterol, high-density-lipoprotein cholesterol, energy intake, estimated glomerular filtration rate, the use of statin, antiplatelet drugs. CVD, cardiovascular disease; DM, diabetes mellitus; HTN, hypertension; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; CI, confidence interval.",34047,17613,44.6,NA,NA,1,NA,NA,NA,NA,NA,NA,7.4,NA,NA,92.1,NA,NA,0,405,133,,1.1,0.87,1.38,1.02,0.87,1.21,47,15,1.66,0.8,3.46,1.66,0.8,3.46,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Schottker et al., 2013",DOI 10.1007/s00125-012-2707-x,James,22,0,NA,1,100-125 mg/dL,0,0,1,0,0,0,0,ESTHER,Germany,2013,2000-2002,7.9,1,"a Adjusted for age, sex, systolic blood pressure, current smoking and total cholesterol/HDL-cholesterol ratio IR, incidence rate per 1,000 person-years; PY, person-years at risk;",9949,5210,62,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"We defined a composite endpoint of CVE of myocardial infarction, stroke or cardiovascular death.",104,39,0.99,0.7,1.41,1.18,0.88,1.58,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Schottker et al., 2013",DOI 10.1007/s00125-012-2707-x,James,22,3,NA,1,"5.7%-6,4%",0,0,1,0,0,0,0,ESTHER,Germany,2013,2000-2002,7.9,1,"a Adjusted for age, sex, systolic blood pressure, current smoking and total cholesterol/HDL-cholesterol ratio IR, incidence rate per 1,000 person-years; PY, person-years at risk;",9949,5210,62,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"We defined a composite endpoint of CVE of myocardial infarction, stroke or cardiovascular death.",207,97,0.96,0.73,1.25,1.09,0.86,1.39,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Sinha et al., 2023",https://doi.org/10.1016/j.cardfail.2022.10.426,James,23,0,NA,0,White,0,0,1,0,0,1,0,Lifetime Risk Pooling Project,USA,2023,NA,19.74464267,1,"Adjusted for age, education, body mass index, hypertension, hyperlipidemia, and smoking.",19170,10621,49.55299948,49.53629602,49.57375132,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"fatal and nonfatal MI was adjudicated using standardized clinical criteria that consisted of at least 2 of the following: electrocardiographic changes consistent with MI, biomarker elevations consistent with myocardial damage, and/or typical chest pain or International Classification of Diseases (ICD) codes (ICD-9 codes 410414 or equivalent).2",NA,NA,1.33,1.08,1.63,1.21,1.05,1.41,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.2,0.93,1.54,1.38,1.09,1.75
"Sinha et al., 2023",https://doi.org/10.1016/j.cardfail.2022.10.426,James,23,0,NA,0,Black,0,0,1,0,0,1,0,Lifetime Risk Pooling Project,USA,2023,NA,19.74464267,1,"Adjusted for age, education, body mass index, hypertension, hyperlipidemia, and smoking.",19170,10621,49.55299948,49.53629602,49.57375132,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,1.56,0.52,4.71,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"fatal and nonfatal MI was adjudicated using standardized clinical criteria that consisted of at least 2 of the following: electrocardiographic changes consistent with MI, biomarker elevations consistent with myocardial damage, and/or typical chest pain or International Classification of Diseases (ICD) codes (ICD-9 codes 410414 or equivalent).2",NA,NA,1.29,0.96,1.73,1.17,0.88,1.56,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.6,1.13,2.27,1.23,0.85,1.78
"Liu et al., 2019",https://onlinelibrary.wiley.com/doi/10.1002/dmrr.3129,James,24,0,NA,0,5.6-7.0 mmol/L,1,1,0,0,0,0,0,Rural Chinese Cohort Study,China,2019,2007-2014,6,1,"age, mean individual income (monthly), marital status, education level, smoking, drinking, physical activity, BMI, TC, TG, HDL‐C, and LDL‐C levels",17248,10439,51.65578618,50.3257017,53.69496255,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,292,134,,1,0.8,1.24,1.14,0.94,1.39,135,58,0.88,0.64,1.23,1.34,1,1.79,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Tran et al., 2022",,James,25,5,ADA FPG + ADA HbA1c,1,Death without Disability,1,0,0,0,0,0,0,NIPPON DATA90,Japan,2022,1990-2012,22,1,". Model 1: adjusted for age, sex, smoking status and drinking status. Model 2: adjustments in model 1 plus cardiovascular risk factors (hypertension, hypertriglyceridemia and low high-density lipoprotein, hypercholesterolemia). Model 3: adjustments in model 1 plus body mass index. Model 4 was adjusted for all variables.",1788,1022,57.51521253,57.35107632,57.63707572,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,131,51,,1.61,1.05,2.49,1.49,0.99,2.25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Hyvarinen et al., 2009",,James,26,1,NA,1,6.1-6.9 mmol/L,0,0,0,0,1,0,0,"Finland, East-West, FINRISK-1987, FINRISK-1992, FINRISK-2002, Helsinki Policemen Study, Vantaa, [Italy, Cremona], [The Netherlands, Hoorn Study], Zuthpen Study, [Sweden, MONICA], Uppsala, [U.K., Goodinge], Newcastle",Finland,2009,NA,10.5,1,". The analysis is adjusted for age, study, BMI, total cholesterol, smoking, and hypertension status.",21706,9862,56.8,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,10,2.04,0.99,4.21,1.05,0.74,1.49,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Hyvarinen et al., 2009",,James,26,2,NA,1,7.8-11.0 mmol/L,0,0,0,0,1,0,0,"Finland, East-West, FINRISK-1987, FINRISK-1992, FINRISK-2002, Helsinki Policemen Study, Vantaa, [Italy, Cremona], [The Netherlands, Hoorn Study], Zuthpen Study, [Sweden, MONICA], Uppsala, [U.K., Goodinge], Newcastle",Finland,2009,NA,10.5,1,". The analysis is adjusted for age, study, BMI, total cholesterol, smoking, and hypertension status.",21706,9862,56.8,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,9,0.9,0.43,1.9,1.43,0.97,2.11,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Hsu et al., 2023","""Prediabetes increases the risk of major limb and cardiovascular events""",James,27,5,ADA FPG + OGTT 2hPG + ADA HbA1c,1,PreDM,0,0,1,0,0,0,0,National Taiwan University Hospital,Taiwan,2023,2014-2019,3.866666667,1,"Model 1: Crude; Model 2: Adjust age, sex, BMI, hypertension, hyperlipidemia, HF, gout, CAD, AF, eGFR",36950,20454,64.00512043,NA,NA,0,97.69169689,NA,NA,5.640243572,NA,NA,NA,NA,NA,75.10390257,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Major adverse cardiovascular events (MACE) were defined as a combination of cardiovascular mortality, non-fatal myocardial infarction, and non-fatal ischemic stroke",678,NA,1.33,1.085,1.641,1.27,1.091,1.476,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Asgari et al., 2024",,James,28,0,NA,0,PreDM & Non-Obese,1,1,1,0,0,0,0,"ARIC, Multi-Ethnic Study of Atherosclerosis, Tehran Lipid and Glucose Study",Iran,2024,1987-2005,16.6,1,"Model adjusted for sex (total population), age, non-HDL-C, education levels, hypertension, FH-CVD, and prevalent CVD (except for CVD)",17433,9682,50,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,907,335,,1.17,1.03,1.34,0.96,0.86,1.08,245,86,1.22,0.93,1.59,0.91,0.73,1.13,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"For TLGS: history of acute coronary syndrome leading to CCU admission, history of percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG), angiographic proven coronary artery disease (i.e.,>50% luminal narrowing of one or more coronary artery), or history of stroke events For ARIC and MESA: History of heart failure (HF), myocardial infarction (MI), coronary revascularization, stroke, or transient ischemic Attack",253,189,1.07,0.9,1.27,1.13,1,1.28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Asgari et al., 2024",,James,28,0,NA,0,PreDM & Obese,1,1,1,0,0,0,0,"Atherosclerosis Risk in Communities, Multi-Ethnic Study of Atherosclerosis, Tehran Lipid and Glucose Study",Iran,2024,1987-2005,16.6,1,"Model adjusted for sex (total population), age, non-HDL-C, education levels, hypertension, FH-CVD, and prevalent CVD (except for CVD)",17433,9682,50,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,467,115,,1.16,1,1.36,1.2,1.04,1.39,154,89,1.3,0.97,1.75,1.37,1.06,1.77,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"For TLGS: history of acute coronary syndrome leading to CCU admission, history of percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG), angiographic proven coronary artery disease (i.e.,>50% luminal narrowing of one or more coronary artery), or history of stroke events For ARIC and MESA: History of heart failure (HF), myocardial infarction (MI), coronary revascularization, stroke, or transient ischemic Attack",313,134,1.07,0.88,1.31,1.15,0.97,1.37,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Yoshida et al., 2022",,James,29,0,NA,1,100-125 mg/dL,0,0,1,1,1,0,0,ARIC,USA,2022,1990-2017,23,1,"Adjusted for age, race/ethnicity, education, body mass index, smoking, blood pressure, cholesterols, menopausal status, uric acids, and antihypertensive or lipid-lowering medications",11262,6409,56.8,56.5,57.1,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,372,173,1.06,0.99,1.12,0.96,0.9,1.02,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CVD outcomes included incident coronary heart disease (CHD) comprising myocardial infarction, CHD death, cardiac procedures, ischemic or hemorrhagic stroke, and a composite atherosclerotic cardiovascular disease (ASCVD), including CHD or stroke.",1286,471,1.07,1,1.14,1,0.93,1.07,NA,1008,333,1.06,1,1.13,0.99,0.93,1.06,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Yoshida et al., 2022",,James,29,3,NA,1,5.7%-6.4%,0,0,1,1,1,0,0,ARIC,USA,2022,1990-2017,23,1,"Adjusted for age, race/ethnicity, education, body mass index, smoking, blood pressure, cholesterols, menopausal status, uric acids, and antihypertensive or lipid-lowering medications",11262,6409,56.8,56.5,57.1,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,260,127,1.14,1.06,1.22,1.12,1.04,1.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CVD outcomes included incident coronary heart disease (CHD) comprising myocardial infarction, CHD death, cardiac procedures, ischemic or hemorrhagic stroke, and a composite atherosclerotic cardiovascular disease (ASCVD), including CHD or stroke.",839,334,1.15,1.07,1.24,1.09,1,1.18,NA,658,237,1.14,1.06,1.22,1.11,1.02,1.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Yoshida et al., 2022",,James,29,2,NA,1,7.8-11.0 mmol/L,0,0,1,1,1,0,0,ARIC,USA,2022,1990-2017,23,1,"Adjusted for age, race/ethnicity, education, body mass index, smoking, blood pressure, cholesterols, menopausal status, uric acids, and antihypertensive or lipid-lowering medications",11262,6409,56.8,56.5,57.1,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,129,78,1.04,0.96,1.21,1.11,1.01,1.21,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CVD outcomes included incident coronary heart disease (CHD) comprising myocardial infarction, CHD death, cardiac procedures, ischemic or hemorrhagic stroke, and a composite atherosclerotic cardiovascular disease (ASCVD), including CHD or stroke.",441,221,1.05,0.97,1.13,1.12,1.02,1.24,NA,342,154,1.05,0.97,1.13,1.1,1,1.22,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Lin et al., 2017",,James,30,5,OGTT 2hPG + WHO FPG,1,PreDM,0,0,0,0,0,0,1,REACTION,China,2017,2011-2012,10,1,"adjusted for age, BMI, physical activity, current smoking status, current drinking status, systolic blood pressure, high-density lipoprotein cholesterol, use of antihypertensive drugs, and a history of cardiovascular disease",250752,164104,57.4,56.81883318,58.46974656,0,6,5.913556038,6.112723894,6,5.80580973,5.805089558,NA,NA,NA,NA,NA,NA,2,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,CKD was defined as eGFR <60 mL/min per 1.73 m,1395,828,1.09,0.98,1.22,1.15,1.02,1.32,NA,NA,NA,NA,NA,NA,NA,NA
"Sasaki et al., 2024",,James,31,5,ADA FPG + OGTT 2hPG,1,PreDM + Normotensive,0,1,1,1,1,1,0,Hiroshima Study,Japan,2024,1982-2014,12.4,1,"age, sex, BMI, smoking habit, drinking habit, hyperlipidemia, hyperuricemia, and renal dysfunction",16564,8487,65.8,NA,NA,0,5.816758633,NA,NA,NA,NA,NA,NA,NA,NA,75.41179667,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,1.33,0.94,1.88,1.19,0.83,1.7,NA,NA,1.08,0.71,1.65,1.35,0.87,2.11,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.23,0.94,1.6,1.25,0.95,1.65,NA,NA,NA,1.15,0.64,2.09,1.26,0.7,2.29,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.41,0.88,2.28,1.37,0.8,2.33
"Sasaki et al., 2024",,James,31,5,ADA FPG + OGTT 2hPG,1,PreDM + Hypertensive,0,1,1,1,1,1,0,Hiroshima Study,Japan,2024,1982-2014,12.4,1,"age, sex, BMI, smoking habit, drinking habit, hyperlipidemia, hyperuricemia, and renal dysfunction",16564,8487,65.8,NA,NA,0,5.816758633,NA,NA,NA,NA,NA,NA,NA,NA,75.41179667,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,1.05,0.77,1.41,0.9,0.67,1.2,NA,NA,1.37,0.92,2.02,0.93,0.66,1.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.91,0.73,1.14,1.15,0.91,1.46,NA,NA,NA,1,0.64,1.57,0.93,0.56,1.55,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.87,0.57,1.32,0.98,0.65,1.48
"Rentsch et al., 2023",,James,32,4,NA,0,PreDM,0,0,0,1,1,1,0,UK Biobank,UK,2023,2006-2010,11.8,1,"s, adjusted for age at study entry, sociodemographics (i.e., ethnicity, deprivation), lifestyle characteristics (i.e., smoking status, alcohol consumption, physical activity, body mass index, waist-hip ratio, processed meat and fruit and vegetable intake), and clinical characteristics (i.e., total cholesterol, estimated glomerular filtration rate, C-reactive protein, diagnosed hypertension, use of antihypertensive medication or statins, and family history of cardiovascular disease).",427435,273317,57.5,57.9,57.2,NA,NA,NA,NA,5.43,5.46,5.41,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3118,1290,1.14,0.99,1.32,1.04,0.92,1.19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3542,1004,1.12,0.97,1.3,1.15,1.04,1.27,NA,NA,NA,NA,NA,NA,NA,NA,NA,3451,1247,1.25,1.11,1.41,1.08,0.98,1.19
"Mehrabani-Zeinabad et al., 2023",,James,33,5,ADA FPG + OGTT 2hPG,1,PreDM & Normal Weight/Overweight - OBESITY DEFINED BY BMI,1,0,1,1,1,0,0,Isfahan Cohort Study,Iran,2023,2001-2017,11.25,1,"Values are adjusted for age, SBP, TG, sex, smoking status, history of heart disease, history of high blood pressure and history of diabetes.",5409,2774,50.98153818,NA,NA,1,90.42560362,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,428,NA,,0.89,0.57,1.38,1.14,0.76,1.72,NA,NA,NA,NA,NA,NA,NA,NA,428,NA,1.9,0.91,3.94,0.74,0.29,1.88,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"s fatal and non-fatal MI, fatal and non-fatal stroke, sudden cardiac death and unstable angina, based on modifed criteria of WHO Expert Committe",428,NA,0.83,0.56,1.23,1.05,0.74,1.48,"IHD included the occurrence of fatal and non-fatal MI, sudden cardiac death (SCD) and unstable angina",428,NA,0.65,0.4,1.04,1.11,0.77,1.62,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Mehrabani-Zeinabad et al., 2023",,James,33,5,ADA FPG + OGTT 2hPG,1,PreDM & Normal Weight/Overweight - OBESITY DEFINED BY WC,1,0,1,1,1,0,0,Isfahan Cohort Study,Iran,2023,2001-2017,11.25,1,"Values are adjusted for age, SBP, TG, sex, smoking status, history of heart disease, history of high blood pressure and history of diabetes.",5409,2774,50.98153818,NA,NA,1,90.42560362,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,253,NA,,1.02,0.47,2.22,1.28,0.83,1.98,NA,NA,NA,NA,NA,NA,NA,NA,253,NA,1.38,0.43,6.54,0.37,0.09,1.56,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"s fatal and non-fatal MI, fatal and non-fatal stroke, sudden cardiac death and unstable angina, based on modifed criteria of WHO Expert Committe",253,NA,0.91,0.42,1.98,1.05,0.72,1.55,"IHD included the occurrence of fatal and non-fatal MI, sudden cardiac death (SCD) and unstable angina",253,NA,0.8,0.31,2.1,1.2,0.81,1.8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Mehrabani-Zeinabad et al., 2023",,James,33,5,ADA FPG + OGTT 2hPG,1,PreDM & Obese- OBESITY DEFINED BY BMI,1,0,1,1,1,0,0,Isfahan Cohort Study,Iran,2023,2001-2017,11.25,1,"Values are adjusted for age, SBP, TG, sex, smoking status, history of heart disease, history of high blood pressure and history of diabetes.",5409,2774,50.98153818,NA,NA,1,90.42560362,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,200,NA,,0.81,0.42,1.56,1.09,0.44,2.68,NA,NA,NA,NA,NA,NA,NA,NA,200,NA,1.33,0.5,3.55,0.66,0.09,4.86,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"s fatal and non-fatal MI, fatal and non-fatal stroke, sudden cardiac death and unstable angina, based on modifed criteria of WHO Expert Committe",200,NA,0.87,0.55,1.38,1.08,0.57,2.05,"IHD included the occurrence of fatal and non-fatal MI, sudden cardiac death (SCD) and unstable angina",200,NA,0.79,0.47,1.33,1.17,0.59,2.29,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Mehrabani-Zeinabad et al., 2023",,James,33,5,ADA FPG + OGTT 2hPG,1,PreDM & Obese - OBESITY DEFINED BY WC,1,0,1,1,1,0,0,Isfahan Cohort Study,Iran,2023,2001-2017,11.25,1,"Values are adjusted for age, SBP, TG, sex, smoking status, history of heart disease, history of high blood pressure and history of diabetes.",5409,2774,50.98153818,NA,NA,1,90.42560362,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,375,NA,,0.7,0.42,1.18,1.16,0.56,2.38,NA,NA,NA,NA,NA,NA,NA,NA,375,NA,1.5,0.6,3.7,1.84,0.65,5.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"s fatal and non-fatal MI, fatal and non-fatal stroke, sudden cardiac death and unstable angina, based on modifed criteria of WHO Expert Committe",375,NA,0.83,0.54,1.29,1.32,0.8,2.16,"IHD included the occurrence of fatal and non-fatal MI, sudden cardiac death (SCD) and unstable angina",375,NA,0.7,0.42,1.15,1.2,0.68,2.11,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Tian et al., 2024",,James,34,5,ADA FPG + OGTT 2hPG,1,PreDM,1,1,0,0,0,0,0,China Chronic Disease and Risk Factors Surveillance,China,2024,2013-2014,6,1,"adjusted for age (5-year group), sex (male or female), residence (urban or rural), education (junior high school and below, high school, college and above), household income ( <¥20,000/year, $¥20,000/year, or not answer/did not know), smoking (never smoked, past smoker, or active smoker), alcohol consumption (excessive, rare/occasional, or nondrinker), physical activity ( <150 min/week or $150 min/week), red meat intake ( <100 g/day or $100 g/day), vegetable and fruit intake ( <400 g/day or $400 g/day), BMI ( <18.5, 18.5–23.9, 24–27.9, $28 kg/m2), hypertension (yes or no), dyslipidemia (yes or no), and self-reported CVD (yes or no).",135405,83576,51.83422695,NA,NA,1,5.758530335,NA,NA,5.493136147,NA,NA,2.82,NA,NA,NA,NA,NA,1,2300,971,,1.02,0.93,1.12,1.12,1.03,1.21,995,443,1.03,0.89,1.19,1.15,1.01,1.31,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Barzilay et al., 2001",,James,35,0,NA,0,IFG,0,0,0,0,1,0,0,The Cardiovascular Health Study,USA,2001,1999,NA,1,age- and race-adjusted.,5712,3293,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1249,747,0.82,NA,NA,1.03,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Barrett-Conner & Ferrara, 1998",,James,36,5,WHO FPG + OGTT 2hPG ,1,IPH,0,0,1,1,0,0,0,The Rancho Bernardo Study,USA,1998,1984-1987,7,1,"s adjustment for age, WHR, triglycerides, HDL cholesterol, hypertension, and current smoking. RH, relative hazards of IPH versus referent group",1858,1089,69.95236814,69.91322314,70.00780234,0,7.324162002,5.314628099,5.504109233,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2.6,1.4,4.7,0.7,0.3,1.6,NA,NA,NA,2.9,1.3,6.4,0.6,0.2,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Hadaegh et al., 2009",,James,37,5,WHO FPG + OGTT 2hPG ,1,IFG/IGT,0,0,1,0,0,0,0,TLGS,Iran,2009,1999-2001,7.6,1,"adjusted for age, systolic blood pressure, diastolic blood pressure, total cholesterol, HDL-cholesterol, smoking and hypertension medication.",4025,2273,53.78685714,52.81777387,55.044121,0,5.736255901,5.845556533,5.63841895,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CVD was defined as any CHD event, stroke (a new neurological deficit that lasted ≥24 h), or cerebrovascular death",61,25,1.07,0.64,1.77,0.99,0.66,1.49,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Imano et al., 2018",,James,38,2,NA,0,PreDM,0,0,0,0,1,0,0,Circulatory Risk in Communities Study (CIRCS),Japan,2018,1963-2018,14.1,1,"adjusted for age, sex (for total subjects), systolic blood pressure, antihypertensive medication use, atrial fibrillation, serum triglycerides, sex-specific quartiles of body mass index, quartiles of serum high-density lipoprotein-cholesterol, time since the last meal and community",7198,4631,58.39974993,57.85871302,59.37580834,0,6.185162545,5.942928093,6.622165952,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,49,17,1.66,0.98,2.82,1.9,1.24,2.9,33,11,2.17,1.12,4.24,1.82,1.09,3.02,15,6,1.24,0.52,2.98,2.03,0.9,4.56,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"De Jong et al., 2020",,James,39,3,NA,0,PreDM,0,0,0,1,0,0,0,UK Biobank,UK,2020,2006-2010,9,1,"*The main effects model is adjusted for age, smoking (never, former, current), BMI, systolic blood pressure, lipid-lowering medication, cholesterol, antihypertensive medication, and the Townsend social deprivation score. **The full interaction model is additionally adjusted for interaction terms between each variable and sex",471399,263024,56.22960337,56.2,56.3,NA,NA,NA,NA,5.46016135,5.4,5.5,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Myocardial Infarcation,1129,390,1.25,1.11,1.4,1.17,1.08,1.27,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Ramezankhani et al., 2022",,James,40,5,ADA FPG + OGTT 2hPG,1,PreDM,0,0,0,0,1,0,0,TLGS,Iran,2022,1999-2018,17.9,1,"adjusted for age, BMI, hypertension, T2D, smoking status, TC, educational level, history of CHD, FH-CVD and lipid lowering drugs.",5349,2903,53.95174799,52.9,55.2,0,5.854271827,5.8,5.9,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.26,0.8,1.98,1.26,0.83,1.9,NA,NA,1.66,1.01,2.7,1.18,0.74,1.89,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Levitzky et al., 2008",,James,41,0,NA,1,100-125 mg/dL,0,0,1,1,0,0,0,Framingham Offspring Cohort,USA ,2008,1983-1998,6.3,1,"age, systolic blood pressure, hypertension treatment, total cholesterol/HDL ratio, current smoking, and BMI.",4058,2163,48.46697881,48,49,0,5.240093642,5.1,5.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cardiovascular disease was defined as any CHD event, stroke, transient ischemic attack (TIA), intermittent claudication, congestive heart failure, or CVD death.",NA,NA,1.4,0.9,2.1,1.1,0.5,1.4,"Coronary heart disease included cases of myocardial infarction, stable and unstable angina pectoris, and CHD death",NA,NA,1.7,1,3,0.9,0.6,1.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Levitzky et al., 2008",,James,41,1,NA,1,110-125 mg/dL,0,0,1,1,0,0,0,Framingham Offspring Cohort,USA ,2008,1983-1998,6.3,1,"age, systolic blood pressure, hypertension treatment, total cholesterol/HDL ratio, current smoking, and BMI.",4058,2163,48.46697881,48,49,0,5.240093642,5.1,5.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Cardiovascular disease was defined as any CHD event, stroke, transient ischemic attack (TIA), intermittent claudication, congestive heart failure, or CVD death.",49,18,2.1,1.2,3.6,1,0.7,1.5,"Coronary heart disease included cases of myocardial infarction, stable and unstable angina pectoris, and CHD death",NA,NA,2.2,1.1,4.4,0.9,0.5,1.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Yi et al., 2017",,James,42,0,NA,0,100-125 mg/dL,1,0,0,0,0,0,0,KOMERIT Study,South Korea,2017,2001-2004,NA,1,"age at baseline, sex (if applicable), smoking status, alcohol use, physical activity, body mass index, systolic blood pressure, and total cholesterol",12845017,7090089,44,45.5,42.9,1,93.4,91.7,94.7,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,112683,56842,,1.19,1.16,1.22,1.2,1.18,1.22,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Djupsjo et al., 2022",,James,43,2,NA,0,7.8-11.1 mmol/L,1,1,0,1,1,1,0,NA,Sweden,2022,2006-2016,3.9,1,"age, sex, date, hospital, and all covariates listed in Table 1, and fnally adjusted for WBC",618694,319543,47.6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,96.4,NA,NA,0,9858,4387,,1.27,1.22,1.31,1.14,1.11,1.18,2335,951,1.39,1.28,1.5,1.17,1.1,1.25,3748,1599,1.29,1.22,1.37,1.17,1.11,1.23,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Myocardial Infarcation,3030,910,1.46,1.35,1.58,1.36,1.28,1.42,NA,NA,NA,NA,NA,NA,NA,NA,NA,1907,754,1.19,1.1,1.3,1.05,0.99,1.13
"Yoshida et al., 2023",,James,44,5,ADA FPG + ADA HbA1c,1,PreDM,0,0,1,1,1,0,0,"Atherosclerosis Risk in Communities, Multi-Ethnic Study of Atherosclerosis, Tehran Lipid and Glucose Study",USA,2023,2022-2023,18.6,1,"Adjusted for age, race/ethnicity, health insurance status, central obesity, hypertension, hypercholesterolemia, current smoking status, antihypertensive medication use, lipid-lowering medication use, and menopause status (women only).",18745,10508,57.3705148,57.06440807,57.76101736,1,99.77259536,98.09795394,101.9089474,5.530642838,5.525970689,5.536603132,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,493,230,1.13,0.99,1.48,1.06,0.86,1.32,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"a MI, CHD death, cardiac procedure (see as mentioned earlier), or ischemic stroke",1646,651,1.18,1.01,1.34,1.08,1,1.28,"myocardial infarction (MI), CHD death, or cardiac procedure (percutaneous coronary interventions, bypass surgery, or coronary revascularization).",1273,439,1.2,1.04,1.37,1.16,1.03,1.32,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Ramezankhani et al., 2023",,James,45,5,ADA FPG + OGTT 2hPG,1,PreDM,0,0,0,1,0,0,0,TLGS,Iran,2023,1999-2018,17.9,1,"r age, smoking status, BMI, SBP, education, TC, antihypertensive and lipid-lowering drugs, and FH-CVD",7518,4141,46.68479915,46.02,47.5,0,5.579573025,5.62,5.53,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"cases of defnite myocardial infarction (MI) diagnosed through electrocardiogram (ECG) and biomarkers, probable MI diagnosed by positive ECG fndings along with cardiac symptoms or signs but with biomarkers showing negative or inconclusive results, unstable angina pectoris, angiographic-proven CHD, and CHD-related death. Nonfatal MI and CHD-related death (including fatal MI) were categorized as hard CHD",NA,NA,1.34,1.05,1.71,1.13,0.94,1.37,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Smith et al., 2002",,James,46,5,WHO FPG + OGTT 2hPG ,0,"OGTT 2hPG (+), FPG (-)",0,0,1,0,0,0,0,The Cardiovascular Health Study,USA,2002,1989-1999,8.5,1,"Age-, race-, and sex- (where appropriate) adjusted",4014,2415.45,73.16230693,NA,NA,1,103.7727952,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,193,96,1.13,0.87,1.45,1.34,1.04,1.72,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Smith et al., 2002",,James,46,5,WHO FPG + OGTT 2hPG ,0,"OGTT 2hPG (+), FPG (+)",0,0,1,0,0,0,0,The Cardiovascular Health Study,USA,2002,1989-1999,8.5,1,"Age-, race-, and sex- (where appropriate) adjusted",4014,2415.45,73.16230693,NA,NA,1,103.7727952,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,60,26,1.1,0.52,2.37,1.54,0.92,2.58,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Liu et al., 2021",,James,47,5,ADA FPG + OGTT 2hPG + ADA HbA1c,1,PreDM,0,0,1,0,0,0,0,NA,China,2021,2011-2017,59.13,1,"The adjusted model included age, sex, hypertension, current smoking, systolic blood pressure, creatinine, low-density lipoprotein cholesterol, glycosylated hemoglobin, high sensitivity C-reactive protein, and baseline statin use",8062,2278,57.8,NA,NA,0,5.86,NA,NA,6.32,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The MACEs included cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke.",NA,NA,NA,NA,NA,0.92,0.56,1.51,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Chen et al., 2024",,James,48,5,ADA FPG + OGTT 2hPG + ADA HbA1c,1,PreDM,1,1,0,0,0,0,0,NHANES 1999-2018,USA,2024,1999-2018,8.6,1,"Models were adjusted for age, sex, race/ethnicity, education level, family income-poverty ratio, drinking status, smoking status, BMI, eGFR, CVD, hypertension, hyperlipidemia, cancer, COPD, depression, anemia, physical activity, HEI scores, use of hypotensive drug, use of lipid-lowering drug except for the corresponding subgroup variables. Diabetes duration, HbA1c and use of antidiabetic drug were adjusted additionally for diabetes subjects",20270,9685,54.35932906,NA,NA,NA,NA,NA,NA,6.186935372,NA,NA,15.5648742,NA,NA,NA,NA,NA,0,1974,NA,,1.15,1.07,1.24,1.08,0.99,1.17,616,NA,1.31,1.12,1.53,1.15,1.01,1.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Song et al., 2022",,James,49,1,NA,0,6.1-7.0 mmol/L,1,0,0,0,0,0,0,Xin Zheng Cohort,China,2022,2011-2019,5.96,1,"adjusted for sex, smoking, alcohol consumption, physical activity, history of CHD, COPD, cancer and stroke, SBP and TC at baseline when stratified by age, adjusted for age, smoking, alcohol consumption, physical activity, history of CHD, COPD, cancer and stroke, SBP and TC at baseline when stratified by sex",59874,31507,65,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,712,329,,0.95,0.85,1.07,0.99,0.89,1.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Han et al., 2023",,James,50,0,NA,0,Intermediate CVH Metrics,0,0,1,0,0,0,0,NHIS-NSC,South Korea,2023,2006-2008,11.9,1,"The analyses were adjusted for sex, age, index year, household income, fasting glucose level, use of antiplatelet drugs, and history of diseases (cancer, myocardial infarction, stroke, or chronic kidney disease).",7948,4385,72.13710367,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"ACE was defined as a composite of hospitalisation for myocardial infarction (ICD-10 codes I21I22), stroke (ICD-10 codes I60  I64), and cardiovascular death (ICD-10 codes I00–I99), using ICD-10 codes.",NA,NA,1,0.85,1.17,0.98,0.83,1.16,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Han et al., 2023",,James,50,0,NA,0,Ideal CVH Metrics,0,0,1,0,0,0,0,NHIS-NSC,South Korea,2023,2006-2008,11.9,1,"The analyses were adjusted for sex, age, index year, household income, fasting glucose level, use of antiplatelet drugs, and history of diseases (cancer, myocardial infarction, stroke, or chronic kidney disease).",7948,4385,72.13710367,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"ACE was defined as a composite of hospitalisation for myocardial infarction (ICD-10 codes I21I22), stroke (ICD-10 codes I60  I64), and cardiovascular death (ICD-10 codes I00–I99), using ICD-10 codes.",NA,NA,0.98,0.86,1.13,0.77,0.66,0.89,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Carpiuc et al., 2010",,James,51,5,ADA FPG & OGTT 2hPG,1,IGT,0,0,0,1,0,0,0,Rancho Bernardo Study,USA,2010,1972-1974,13.2,1,"Model 1, adjusted for age only; model 2, model 1 þ WHR, hypertension, triglycerides, HDL-C; model 3, model 2 þ physical activity, current smoking, alcohol intake, education, and current estrogen (women).",2006,1184,70.66390828,70.5,70.9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2.35,NA,4.59,1.65,NA,4.42,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Song et al., 2023",,James,52,5,ADA FPG or WHO FPG or ADA HbA1c or IEC HbA1c,1,PreDM,0,0,1,0,0,0,0,"Fuwai Hospital, Beijing",China,2023,2013,6.1,1,"Adjusted for age, sex, medical history of hypertension, hyperlipidemia, smoking status, alcoholic consumption, body mass index, heart rate, total cholesterol, LDL, HDL, hsCRP, D-Dimer and triple vessel disease;",1532,488,59.21001958,NA,NA,0,5.892343342,NA,NA,6.401879896,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"MACE, which was a composite endpoint of all-cause death, non-fatal myocardial infarction and repeated ischemia-driven revascularization",58,11,2.213,0.731,6.696,1.597,0.959,2.658,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Golabi et al., 2023",,James,53,5,ADA FPG or ADA HbA1c,1,PreDM,1,0,0,0,0,0,0,NHANES 1988-1994,USA,2023,1988-2019,26.7,1,"Models were adjusted for age, sex, race, income, education, smoking, physical activity, and healthy eating.",11231,6296.0986,43.41,NA,NA,NA,NA,NA,NA,NA,NA,NA,4.58,NA,NA,NA,NA,NA,0,NA,NA,,4.59,1.39,15.19,1.12,0.35,3.56,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Gordon-Dseagu et al., 2015",,James,54,3,NA,0,PreDM,1,0,1,0,0,0,0,Health Survey for England (HSE),UK,2015,2003-2013,7,1,"Age, sex, smoking, SES, BMI",22106,11908,52,NA,NA,NA,NA,NA,NA,5.52,NA,NA,2.28897132,NA,NA,NA,NA,NA,0,NA,NA,,0.99,0.83,1.18,0.92,0.77,1.09,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,cardiovascular disease (390–459; I00-I99),NA,NA,1.06,0.76,1.46,1.08,0.81,1.45,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Liu et al., 2017",,James,55,0,NA,0,IFG,0,1,0,0,0,0,0,ChinaMUCA & China Cardiovascular Health Study,China,2017,1998-2008,7.8,1,"Adjusted for age (every 10 years), gender, body mass index, smoking status (never smoker, former smoker, current smoker), drinking status (never drinker, drinker), work-related physical activity, education, hypertension status (yes vs. no), high triglyceride (yes vs. no), region (south, north), area (urban, rural), and family history of atherosclerotic cardiovascular disease (ASCVD); gender, region and area were not adjusted for in corresponding subgroup analyses.",18610,9681,48.44898442,NA,NA,1,94.92944653,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"ASCVD is defined as the first occur-rence of non-fatal myocardial infarction (MI), CHDdeath, or fatal or non-fatal stroke.",120,NA,1.22,0.86,1.73,0.88,0.65,1.18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Yuan et al., 2021",,James,56,5,ADA FPG or ADA HbA1c,1,PreDM,1,0,1,0,0,0,0,"Fuwai Hospital, Beijing",China ,2021,2004-2011,7.5,1,"sex, history of smoking, previous stroke, hypertension, age, peripheral artery disease, hyperlipidemia, left main disease, chronic kidney dis- ease, body mass index, treatment strategy, left ventricular ejec- tion fraction (LVEF), clinical presentation and SYNTAX score (≤22, 23–32 or ≥33)",8891,1809,61.08246541,NA,NA,0,6.178922506,NA,NA,6.233899449,NA,NA,NA,NA,NA,NA,NA,NA,0,240,42,,0.83,0.57,1.23,1,0.84,1.19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,437,78,0.91,0.68,1.21,1.01,0.89,1.15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Hennessey et al., 2020",,James,57,5,NA,1,PreDM,0,0,0,0,0,0,1,CURE-CKD,USA,2020,2006-2017,NA,1,NA,544253,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,CKD was defined by estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 or urine albumin-to-creatinine ratio >30 mg/g based upon two or more measurements >90 days apart and administrative codes,NA,NA,1.06,1.04,1.09,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Lee et al., 2018",,James,58,5,ADA FPG or OGTT 2hPG,1,NFG -> IFG,1,0,0,1,1,0,0,NHIS-HEALS,South Korea,2018,2002-2013,8,1,"djusted for age, sex, socioeconomic status, physical activity, smoking status, alcohol consumption, body mass index, blood pressure, total cholesterol, Charlson comorbidity index, and baseline fasting glucose level",260487,110678.478,53.77912103,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,1601,388,1213,1.09,0.97,1.22,1.07,1.01,1.14,NA,NA,NA,NA,NA,NA,NA,NA,1274,484,1.03,0.94,1.14,1.05,0.97,1.14,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Myocardial Infarcation,225,42,1.11,0.78,1.57,1.1,0.93,1.31,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Succurro et al., 2020",,James,59,5,ADA FPG or OGTT 2hPG or ADA HbA1c,1,PreDM,0,0,1,0,0,0,0,CATAMERI,Italy,2020,2006-2019,5.6,1,"age; BMI; smoking status; SBP and DBP; total, LDL, and HDL cholesterol; triglycerides; HOMA-IR index; hs-CRP; fibrinogen; and WBC count.",2118,1064,54.80453258,54.53759398,55.0740038,1,94.47119924,92.58270677,96.37760911,5.524362606,5.503007519,5.545920304,6.132011331,9.581404175,2.715037594,NA,NA,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Composite CVD was defined by the presence of CHD and/or cerebrovascular disease.,NA,NA,1.16,0.42,3.14,1.21,0.63,2.32,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Balkau 2004,,James,60,5,WHO FPG &/or OGTT 2hPG,1,5-year Hazard Ratio,0,1,0,0,0,0,0,DECODE,Europe,2004,1995,5.2,1,"adjusted for age and centre, and then adjusted for all factors",25413,8907,NA,NA,NA,0,5.529902019,5.4,5.6,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.84,0.84,4.01,1.38,1.04,1.84,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Balkau 2004,,James,60,5,WHO FPG &/or OGTT 2hPG,1,10-year Hazard Ratio,0,1,0,0,0,0,0,DECODE,Europe,2004,1995,5.2,1,"adjusted for age and centre, and then adjusted for all factors",25413,8907,NA,NA,NA,0,5.529902019,5.4,5.6,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.73,1.11,2.68,1.22,1,1.49,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Thrainsdottir et al., 2005",,James,61,5,WHO FPG or OGTT 2hPG,1,Abnormal Glucose Regulation,0,0,0,1,0,0,0,Reykjavik Study,Iceland,2005,1996-2001,21.5,1,"adjusted for dissimilarities in age, body mass index, previous ischaemic heart disease, systolic blood pressure, blood cholesterol and smoking habits",17979,9412,54.2170421,54.86908202,53.50068869,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Myocardial Infarcation,203,106,1.2,1,1.5,1.1,0.9,1.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Thrainsdottir et al., 2005",,James,61,5,WHO FPG or OGTT 2hPG,1,Abnormal Glucose Regulation + HF,0,0,0,1,0,0,0,Reykjavik Study,Iceland,2005,1996-2001,21.5,1,"adjusted for dissimilarities in age, body mass index, previous ischaemic heart disease, systolic blood pressure, blood cholesterol and smoking habits",119,55,61.48487395,61.7,61.3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Myocardial Infarcation,17,7,1.6,0.9,2.9,1.5,1,2.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA